SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

Search

Innate Pharma SA

Uždarymo kaina

1.812 1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.732

Max

1.832

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-25M

Pardavimai

12M

Pelno marža

-200.599

Darbuotojai

168

EBITDA

-26M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+136.73% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

160M

Ankstesnė atidarymo kaina

0.81

Ankstesnė uždarymo kaina

1.812

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Innate Pharma SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 22:45; UTC

Svarbiausios naujienos

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025-03-31 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise After Monday's Selloff -- Market Talk

2025-03-31 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-03-31 22:33; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025-03-31 22:28; UTC

Uždarbis

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke Swings to Loss for 2024 >000002.SZ

2025-03-31 21:47; UTC

Svarbiausios naujienos

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025-03-31 21:44; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025-03-31 21:21; UTC

Rinkos pokalbiai

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025-03-31 21:18; UTC

Svarbiausios naujienos

Copper Is 2025's Hottest Commodity -- Update

2025-03-31 21:09; UTC

Svarbiausios naujienos

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025-03-31 21:02; UTC

Uždarbis

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025-03-31 21:01; UTC

Uždarbis

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025-03-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-03-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-03-31 20:37; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025-03-31 20:17; UTC

Svarbiausios naujienos

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025-03-31 20:13; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025-03-31 20:03; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025-03-31 19:09; UTC

Rinkos pokalbiai

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025-03-31 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025-03-31 18:54; UTC

Rinkos pokalbiai

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025-03-31 18:40; UTC

Rinkos pokalbiai

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025-03-31 18:34; UTC

Rinkos pokalbiai

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025-03-31 18:28; UTC

Rinkos pokalbiai

Gold Climbs to Close Out Quarter -- Market Talk

2025-03-31 18:03; UTC

Svarbiausios naujienos

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Akcijų palyginimas

Kainos pokytis

Innate Pharma SA Prognozė

Kainos tikslas

By TipRanks

136.73% į viršų

12 mėnesių prognozė

Vidutinis 4.403 EUR  136.73%

Aukščiausias 5.7 EUR

Žemiausias 3.1 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innate Pharma SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.802 / 1.888Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.